Biogen Idec News
DaVita HealthCare entered into a strategic liaison with Myriad Genetics.
Is Elan Pushing Its Luck?
Elan Likely To Receive Higher Takeout Bids
Biogen Idec was a winner within the drugs industry, rising $3.05 (1.5%) to $210.80 on average volume
Perrigo has purchased Fera's eye-care portfolio.
This deal is in line with Teva's strategy of strengthening its position in the respiratory therapeutic area.
This deal signifies J&J's attempt to strengthen its prostate cancer franchise especially once Zytiga loses exclusivity.
Celgene presented positive results on apremilast from a phase II study.